Pulmonary Drugs Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Pulmonary</strong> <strong>Drugs</strong> <strong>Market</strong> Research Report: Forecast up to 2024<br />
Global <strong>Pulmonary</strong> <strong>Drugs</strong> <strong>Market</strong>: Snapshot<br />
The global pulmonary drugs market has been the key area of focus and the most crucial<br />
market for the healthcare industry in the last couple of years. However, the market is<br />
expected to witness a significant decline over the forecast period with a -6.3% CAGR from<br />
2016 to 2024. The market is anticipated to fall to US$28,082.1 mn from a valuation of<br />
US$48,039.7 mn in 2015. Keeping aside the tremendous fall of the global pulmonary drugs<br />
market, it has been expected that the market will find growth prospects from the growing<br />
number of respiratory diseases and the fact that they are becoming the leading cause of<br />
deaths across the globe at present, especially among the aged population.<br />
According to the Forum of International Respiratory Societies (FIRS), chronic obstructive<br />
pulmonary disease affects over 200 million people across the globe and is also one of the<br />
leading causes of death globally. On the other, over 235 million people across the globe<br />
suffer from asthma. Owing to these alarming statistics, the consumption of pulmonary drugs<br />
is likely to gain momentum, thus providing growth opportunities to the market in spite of<br />
the negative CAGR. <strong>Pulmonary</strong> drugs are also being employed for the treatment of<br />
conditions such as cystic fibrosis, respiration-related disorders, pulmonary arterial<br />
hypertension (PAH), and allergic rhinitis. The launch of many effective and innovative<br />
drugs in the global market for pulmonary drugs is also anticipated to have a positive impact<br />
on the growth of the market in the coming years.<br />
This exhaustive report includes a 360° view of the <strong>Pulmonary</strong> <strong>Drugs</strong> <strong>Market</strong>. Browse<br />
through this 196-page report to know what factors will shape the market during the<br />
period 2016-2024<br />
http://www.transparencymarketresearch.com/pulmonary-drugs-market.html
Global <strong>Pulmonary</strong> <strong>Drugs</strong> <strong>Market</strong>: Key Players<br />
Some of the leading players in the market are Actelion Pharmaceuticals, Inc., Boehringer<br />
Ingelheim GmbH, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline<br />
plc, F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, AstraZeneca plc, and Sunovion<br />
Pharmaceuticals Inc.<br />
Medical Professionals to Prefer Combination <strong>Drugs</strong> among All Others<br />
Based on drug classes, the global market for pulmonary drugs is classified into combination<br />
drugs, anticholinergics, short acting beta2-agonists, vasodilators, antihistamines, long-acting<br />
beta2-agonists, and inhaled corticosteroids, and others such as antileukotrienes, antibiotics,<br />
enzymes, and monoclonal antibodies. Among these, the segment of combination drugs held<br />
the leading share of 27.4% in 2015 closely followed by inhaled corticosteroids with a share<br />
of 16.7% in the same year in the global pulmonary drugs market. The sales of combination<br />
drugs is likely to remain high throughout the forecast period as they are considered to be<br />
comparatively safer than the other drugs. Moreover, the advent of triple combination drugs<br />
is further projected to propel the growth of the global pulmonary drugs market over the<br />
course of the forecast period.<br />
Advent of Middle-income Classes to Catapult Demand in Asia Pacific<br />
Based on geography, the global market for pulmonary drugs has been classified into Asia<br />
Pacific, North America, Europe, the Middle East and Africa, and Latin America. In 2015,<br />
North America led the global pulmonary drugs market with a share of 41% with Europe<br />
closely following with a share of 32.4% in the same year. The growing use of pulmonary<br />
drugs in these regions can be attributed to the advanced healthcare infrastructure coupled<br />
with high awareness regarding treatment of pulmonary diseases. However, the rise of<br />
middle-income classes and their growing expenditure on healthcare is expected to lift Asia<br />
Pacific as a prominent region in the global market.<br />
Request a brochure of this report to know what opportunities will emerge in the<br />
rapidly evolving <strong>Pulmonary</strong> <strong>Drugs</strong> <strong>Market</strong> during 2016- 2024<br />
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16751
About Us<br />
Transparency <strong>Market</strong> Research (TMR) is a market intelligence company, providing<br />
global business information reports and services. Our exclusive blend of quantitative<br />
forecasting and trends analysis provides forward-looking insight for thousands of decision<br />
makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary<br />
data sources and various tools and techniques to gather, and analyze information. Our<br />
business offerings represent the latest and the most reliable information indispensable for<br />
businesses to sustain a competitive edge.<br />
Each TMR syndicated research report covers a different sector – such as pharmaceuticals,<br />
chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and<br />
technology. These reports provide in-depth analysis and deep segmentation to possible<br />
micro levels. With wider scope and stratified research methodology, TMR’s syndicated<br />
reports strive to provide clients to serve their overall research requirement.<br />
US Office Contact<br />
90 State Street, Suite 700<br />
Albany, NY 12207<br />
Tel: +1-518-618-1030<br />
USA – Canada Toll Free: 866-552-3453<br />
Email: sales@transparencymarketresearch.com<br />
Website: http://www.transparencymarketresearch.com
Change language